TLR9, toll like receptor 9, 54106

N. diseases: 457; N. variants: 11
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0702166
Disease: Acne
Acne
0.010 AlteredExpression disease BEFREE Requirement for TLR9 in the immunomodulatory activity of Propionibacterium acnes. 15778393 2005
CUI: C2936664
Disease: Acquired Hypogammaglobulinemia
Acquired Hypogammaglobulinemia
0.010 AlteredExpression disease BEFREE TLR9 stimulation of B-cells induces transcription of p53 and prevents spontaneous and irradiation-induced cell death independent of DNA damage responses. Implications for Common variable immunodeficiency. 28973009 2017
CUI: C0001175
Disease: Acquired Immunodeficiency Syndrome
Acquired Immunodeficiency Syndrome
0.010 Biomarker group LHGDN Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. 18806803 2008
CUI: C0151332
Disease: Active tuberculosis
Active tuberculosis
0.010 GeneticVariation disease BEFREE Our findings in two independent samples indicated that SNPs in TLR8 and TLR9 were associated with the development of TB, and highlight that SNPs may have different effects on disease pathogenesis and progression. 30424735 2018
CUI: C0582415
Disease: Acute asthma
Acute asthma
0.010 Biomarker disease BEFREE MHT could mitigate the pathological changes of acute asthma-like syndrome through inhibition of the TLR9 pathway. 30415587 2018
CUI: C3536663
Disease: Acute deep venous thrombosis
Acute deep venous thrombosis
0.010 Biomarker disease BEFREE Animal models suggest that toll-like receptor 9 (TLR9) promotes thrombus resolution after acute deep venous thrombosis (DVT). 26938157 2016
CUI: C0856825
Disease: Acute GVH disease
Acute GVH disease
0.020 GeneticVariation disease BEFREE A retrospective analysis of the first cohort (n=293) showed that the homozygous CC gene variant of TLR9 (1486) compared with TC/TT gene variants was significantly associated with a markedly improved 5-year TRM (11.7 versus 36.4%, P<0.003), 5-year OS (86.1 vs 48.3%, P<0.001) and a lower relapse rate (13.2 vs 33.3%, P<0.007), whereas the occurrence of acute GVHD was not different. 19252531 2009
CUI: C0856825
Disease: Acute GVH disease
Acute GVH disease
0.020 GeneticVariation disease BEFREE We found that two tagSNPs in the TLR9 gene in the donor side, +1174 A/G (rs352139) and +1635 C/T (rs352140), influenced the risk of acute GVHD (aGVHD) and CMV reactivation. 24121213 2014
CUI: C0162565
Disease: Acute intermittent porphyria
Acute intermittent porphyria
0.010 AlteredExpression disease BEFREE Conversely, polyinosinic-polycytidylic acid-induced inflamed pancreatic tissue in murine AIP exhibited increased expression of type I IFNs and IL-33 (and downstream IL-33 cytokines such as IL-13 and TGF-β1). pDCs stimulated by type I IFN were the source of the IL-33 because purified populations of these cells isolated from the inflamed pancreas produced a large amount of IL-33 upon activation by TLR9 ligands, and such production was abrogated by the neutralization of type I IFN. 28373582 2017
CUI: C1279945
Disease: Acute interstitial pneumonia
Acute interstitial pneumonia
0.010 AlteredExpression disease BEFREE Conversely, polyinosinic-polycytidylic acid-induced inflamed pancreatic tissue in murine AIP exhibited increased expression of type I IFNs and IL-33 (and downstream IL-33 cytokines such as IL-13 and TGF-β1). pDCs stimulated by type I IFN were the source of the IL-33 because purified populations of these cells isolated from the inflamed pancreas produced a large amount of IL-33 upon activation by TLR9 ligands, and such production was abrogated by the neutralization of type I IFN. 28373582 2017
CUI: C0085669
Disease: Acute leukemia
Acute leukemia
0.010 GeneticVariation disease BEFREE <b>Methods</b>: The Therapeutic Advances in Childhood Leukemia and Lymphoma Phase I consortium performed a pilot study on 3 patients with MRD positive acute leukemia after an initial remission on conventional chemotherapy (TACL T2009-008) with the TLR 9 agonist (GNKG168). 31530240 2019
CUI: C0023449
Disease: Acute lymphocytic leukemia
Acute lymphocytic leukemia
0.010 Biomarker disease BEFREE The aim of the present study was to evaluate the expression of TLR1, TLR3, TLR4, TLR7 and TLR9 in peripheral blood mononuclear cells (PBMCs) in patients with ALL and prior to any treatment. 27277333 2016
CUI: C2930826
Disease: Acute malaria
Acute malaria
0.020 GeneticVariation disease BEFREE To further delineate the impacts of FcγRIIIA and TLR9 in SMA pathogenesis, the associations between FcγRIIIA -176F/V and TLR9 -1237T/C variants, SMA (hemoglobin [Hb] < 6.0 g/dl), and circulating IFN-γ levels were investigated in children (n = 301) from western Kenya with acute malaria. 23045477 2012
CUI: C2930826
Disease: Acute malaria
Acute malaria
0.020 Biomarker disease BEFREE Our data provide unprecedented evidence that TLR9 and MyD88 are essential to initiate IL12 and IFNgamma responses and favor host hyperresponsiveness to TLR agonists resulting in overproduction of proinflammatory cytokines and the sepsis-like symptoms of acute malaria. 19297619 2009
CUI: C0155626
Disease: Acute myocardial infarction
Acute myocardial infarction
0.010 Biomarker disease BEFREE CD11c and TLR9, which are DC surface markers, showed a significantly increased expression in mice with AMI. 28337868 2017
CUI: C0001339
Disease: Acute pancreatitis
Acute pancreatitis
0.030 Biomarker disease BEFREE Conversely, treatment of mice with TLR9 antagonists, mimicking AVC, exerted protective effects against AP. 31726046 2020
CUI: C0001339
Disease: Acute pancreatitis
Acute pancreatitis
0.030 AlteredExpression disease BEFREE Furthermore, CpG‑ODN1826 administration induced an increase in TLR9 expression levels compared with the AP alone group at 0, 3, 6 and 12 h. TNF‑α in the CpG + AP 12 h group was upregulated compared with that in the CpG + AP 3 and 6 h groups; however, no change was observed between 3 and 6 h. Thus, these data indicate that CpG‑ODN1826 aggravates sodium taurocholate‑induced pancreas damage in rats. 30106134 2018
CUI: C0001339
Disease: Acute pancreatitis
Acute pancreatitis
0.030 Biomarker disease BEFREE Genetic deletion and pharmacologic antagonism demonstrate that specific DAMP receptors, including Toll-like receptor (TLR) 4, TLR9, and P2X7, are also required for inflammation in experimental acute pancreatitis. 22415665 2012
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.010 Biomarker group BEFREE The aim of the study was to evaluate the clinical significance of tissue expression and serum concentration of TLR-2, TLR-4, TLR-7 and TLR-9 in patients with esophageal squamous cell carcinoma and gastro-esophageal junction adenocarcinoma. 29968427 2019
CUI: C0152013
Disease: Adenocarcinoma of lung (disorder)
Adenocarcinoma of lung (disorder)
0.010 GeneticVariation disease BEFREE We generated a mouse model of lung adenocarcinoma (ADC) mutated for K-ras (K-ras(LA1) ), with and without TLR9 inactivation (K-ras(LA1) TLR9(-/-) and K-ras(LA1) TLR9(+/+) , respectively). 23913633 2014
CUI: C0206677
Disease: Adenomatous Polyps
Adenomatous Polyps
0.010 AlteredExpression disease BEFREE TLR9 expression was higher in hyperplastic or adenomatous polyps compared to other polyp types. 22371291 2012
CUI: C0001486
Disease: Adenovirus Infections
Adenovirus Infections
0.010 Biomarker group BEFREE Keratitis similar to wild type mice was observed in TLR2, TLR9 and IL-1R knockout mice, but was reduced in TLR2/9 double knockout mice, consistent with synergy of TLR2 and TLR9 in the response to adenovirus infection. 27528076 2017
CUI: C0751606
Disease: Adult Acute Lymphocytic Leukemia
Adult Acute Lymphocytic Leukemia
0.010 Biomarker disease BEFREE The aim of the present study was to evaluate the expression of TLR1, TLR3, TLR4, TLR7 and TLR9 in peripheral blood mononuclear cells (PBMCs) in patients with ALL and prior to any treatment. 27277333 2016
CUI: C0278764
Disease: Adult Burkitt Lymphoma
Adult Burkitt Lymphoma
0.030 Biomarker disease BEFREE These results suggest that the Namalwa Burkitt lymphoma line may serve as a useful cell-based assay for the detection of novel TLR9 agonists as well as a model to further explore the regulation of TLR9 expression and signaling. 15894327 2005
CUI: C0278764
Disease: Adult Burkitt Lymphoma
Adult Burkitt Lymphoma
0.030 Biomarker disease BEFREE TLR9 triggering in Burkitt's lymphoma cell lines suppresses the EBV BZLF1 transcription via histone modification. 20514021 2010